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Infection with oncogenic human papillomavirus (HPV) is considered to be the major risk to cervical cancer. This study analyzed the
influence of HPV infection on cytokine intralesional levels in cervical lesion in the presence or not of HIV infection. Cervical biopsies from
42 women were studied. HPV detection and typing were performed using amplified DNA hybridized with sequence-specific primers, and
cytokine intralesional levels were detected using ELISA. HPV16+ biopsies exhibited increased IFN-g and IL-10 when compared to HPV16
(P = 0.03 and 0.04, respectively). HPV18+ biopsies exhibited decreased TNF-a (P = 0.009) and IFN- g (P = 0.01) when compared to
HPV18. In accordance to HIV status, HIV/HPV16+ patients exhibited increased IFN-g when compared to those presenting HIV/
HPV16 (P = 0.007). HIV/HPV18+ patients presented decreased IFN-g when compared to HIV/HPV18 (P = 0.02). These results
suggest that the presence of HPV16 infection may influence cervical lesion installation, and irrespective of HIV status, HPV18 infection may
be more aggressive than HPV-16.
D 2005 Elsevier Inc. All rights reserved.
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Cancer of the cervix accounts for almost 12% of all
cancers in women and represents the second most frequent
gynecological malignancy in the world (Pisani et al.,
2002). Infection with high-risk human papillomavirus
(HPV) types, particularly HPV 16 and 18, is considered
to be the major risk factor for cervical cancer development
(Schiffman et al., 2000; Zur Hausen, 1999). Although in
70–90% of HPV-infected individuals the virus is usually
cleared (Ho et al., 1998), in a small percentage of patients0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.029
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E-mail address: anapaula@eerp.usp.br (A.P.M. Fernandes).the virus persists and may lead to the development of high-
grade squamous intraepithelial lesions (HSILs) (Zur
Hausen, 2002).
Cytokines play an important role in the defense against
HPV infection, modulating viral replication and polarizing
the immune response to the Th1 or Th2 pattern (Zur
Hausen, 2002). A predominance of Th1 polarization, with
production of IFN-g, has been associated with the
clearance of HPV infection and regression of SIL (Stellato
et al., 1997). In addition, in the presence of TNF-a, an
antiviral effect with growth-inhibitory and virus-suppressive
properties is also observed (Bachmann et al., 2002). In
contrast, immunosuppressive cytokines (IL-10, TGF-h) are
associated with the persistence of HPV infection and
progression to SIL by suppressing cell-mediated immunity05) 294–298
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2002).
Recent studies have reported an increased prevalence and
persistence of HPV 16 and 18 in the genital tract of HIV-
positive women. The predominance of Th2 cytokine polar-
ization in HIV-positive women may explain, in part, the
susceptibility to recurrent genital tract infections and SIL
occurrence, permitting the development of neoplastic
atypias (Ahmed et al., 2002; Gonc¸alves et al., 2003; Olaitan
et al., 1998).
In the present study, we evaluated cytokine intrale-
sional levels (TNF-a, IL-10, and IFN-g) in women
presenting with low-grade (LG) or high-grade (HG) SIL,
infected with HPV, and presenting or not HIV infection as
co-morbidity.Results
Frequency of HPV and HIV infection
All patients analyzed were infected with HPV and were
stratified in 8 subgroups, according to the HPV type and
HIV infection:
a. HIV negative, HPV16+ (n = 11);
b. HIV negative, HPV18+ (n = 6);
c. HIV negative, HPV16+, HPV18+ (n = 3);
d. HIV negative, other HPV positive (n = 2);
e. HIV positive, HPV16+ (n = 10);
f. HIV positive, HPV18+ (n = 1);
g. HIV positive, HPV16+, HPV18+ (n = 2);
h. HIV positive, other HPV positive (n = 7).
HPV infection and intralesional cytokine levels
When patients were stratified according to HIV
infection or SIL severity, no significant differences were
found. Similarly, when HIV-positive patients were strati-
fied according to the severity of the lesion and according
to CD4 T-cell count, no significant differences were
observed.Table 1
Intralesional cytokine levels (pg/50 AL) stratified according to the type of HPV i
Cytokine HPV16 HPV18
Negative
(n = 16)
Positive
(n = 26)
Negative
(n = 30)
Positive
(n = 12)
IFN-g 83
(8–116)
112
(8–146) 0.03T
113
(8–146)
87
(8–132) 0.01T
TNF-a 4
(0–59)
8
(0–85) 0.49T
14
(0–85)
0
(0–45) 0.009T
IL-10 30
(0–415)
227
(0–390) 0.04T
125
(0–391)
51
(0–415) 0.97T
Median (range) values are also shown.
* P value.When patients were stratified according to HPV type,
those presenting with HPV16 infection exhibited increased
intralesional levels of IFN-g and IL-10, compared to those
without HPV16 infection (P = 0.03 and 0.04, respectively).
On the other hand, patients presenting with HPV18
infection exhibited decreased TNF-a and IFN-g intrale-
sional levels when compared to those without HPV18
infection (P = 0.009 and P = 0.01, respectively).
To avoid the confounding influence of HPV 16 on HPV
18 and vice versa on the comparisons with patients who did
not harbor these types, additional groups were assigned.
Patients presenting exclusively with HPV 16 infection
exhibited increased IL-10 levels when compared to those
with other HPV types excluding HPV 18 (P = 0.008),
whereas patients presenting exclusively with HPV18 infec-
tion exhibited IL-10 levels closely similar to those observed
for other HPV types excluding HPV16 (P = 0.32). On the
other hand, patients presenting exclusively with HPV18
infection exhibited decreased levels of TNF-a (P = 0.005)
and of IFN-g (P = 0.04) when compared with those
presenting exclusively with HPV16 infection. Finally,
patients presenting both HPV16 and 18 exhibited closely
similar levels of TNF-a, IFN-g, and IL-10 when compared
to patients harboring other HPV types. The results that
revealed significant associations regarding intralesional
cytokine levels are shown in Table 1.
HPV and HIV infection associated with intralesional
cytokine levels
When patients were stratified according to HIV status
and HPV type, specimens collected from HIV+/HPV16+
patients exhibited increased IL-10 levels when compared to
HIV+/HPV16 patients (P = 0.04), as illustrated in Table
2. Regarding HIV-negative patients, those presenting
HPV16 infection exhibited increased intralesional IFN-g
levels compared to patients without HPV16 infection (P =
0.007). In addition, HIV/HPV18+ patients presented
decreased intralesional IFN-g levels compared to HIV/
HPV18 patients (P = 0.02).
With regard to the severity of SIL and HPV type, patients
presenting with HSIL/HPV16 showed a trend increase ofnfection (16 or 18) and HIV status
HIV negative HIV negative
HPV16
(n = 08)
HPV16+
(n = 14)
HPV18
(n = 13)
HPV18+
(n = 09)
58
(8–102)
112
(8–146) 0.007T
116
(8–146)
77
(8–102) 0.02T
4
(0–19)
0
(0–76) 0.91T
8
(0–76)
0
(0–18) 0.12T
41
(0–415)
142
(0–391) 0.46T
139
(0–391)
51
(0–415) 1.00T
Table 2
Intralesional cytokine levels (pg/50 AL) of TNF-a and IL-10 stratified
according to the presence of HIV infection and to the absence of HPV16
infection
Cytokine HIV positive HPV16 negative
HPV16
(n = 08)
HPV16+
(n = 12)
LG-SIL
(n = 09)
HG-SIL
(n = 07)
TNF-a 5
(0–59)
4
(0–85) 0.41T
0
(0–12)
17
(0–59) 0.05T
IL-10 8
(0–337)
278
(0–338) 0.04T
15
(0–337)
51
(0–415) 0.60T
Median (range) values are also shown.
* P value.
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HPV16 (P = 0.05), as shown in Table 2.Discussion
Several authors have reported that the immune response
against HPV and HIV infection shows polarization to the
Th2 cytokine profile, either locally or at the systemic level,
facilitating neoplastic transformation and predisposing
women to SIL and cervical cancer (Ahmed et al., 2002;
Olaitan et al., 1998). To our knowledge, this is the first
study that analyzes the intralesional cytokine levels in
women presenting with HPV-infection, stratified according
to HIV status and SIL severity.
IFN-g mediates cellular immunity and is effective in host
defense against viral infections and tumors, whereas IL-10
mediates humoral immunity against extracellular antigens
and is immunoinhibitory, stimulating tumor growth (Clerici
and Shearer, 1994; El-Sherif et al., 2001; Olaitan et al., 1998;
Rengarajan et al., 2000). In this series, we observed that the
presence of HPV16 was associated with increased IL-10 and
IFN-g intralesional levels when compared to patients who
harbored other HPV types. Furthermore, the presence of an
additional risk factor, i.e., the superimposed HIV infection
(HIV+/HPV16+), was associated with increased intrale-
sional levels of IL-10, whereas HIV/HPV16+ patients
presented increased IFN-g levels. These findings support the
idea that increased IL-10 in cervical lesions of HIV-positive
women may facilitate neoplastic transformation in the
presence of HPV16, which has long been considered an
important agent endowed with a high oncogenic potential.
These findings are in accordance with those reported by
Crowley-Nowick et al. (2000) in cervico-vaginal secretions;
however, the present study is the first to describe intrale-
sional cytokine measurements in SIL fragments infected
with HPV16 and HPV18. In addition, the findings of the
present study regarding the increased IL-10 levels in biopsies
from HIV-positive patients and increased IFN-g levels in
biopsies from HIV-negative patients corroborate the ample
evidence in the literature that HIV-infected patients are at risk
for HPV-16-associated dysplasia and malignancy based onprospective studies (Minkoff et al., 1998). Finally, the
present results suggest that the intralesional cytokine profile
may modulate anti-tumor activity, a finding that may have
practical implications in the development of immunotherapy
for cervical cancer, particularly for HIV-infected women.
HPV18-infected women, irrespective of HIV status, showed
reduced intralesional levels of TNF-a and INF-g in relation
to those who did not harbor HPV18, even after excluding
patients presenting HPV 16. These findings differ from those
observed for HPV16 patients of this series, suggesting that
the HPV type may induce distinct immune inhibitory
response, sometimes increasing IL-10 and sometimes
decreasing TNF-a and IFN-g. Corroborating this idea, when
both HPV 16 and 18 were found together, no particular
difference in terms of cytokine intralesional levels was
observed when compared to other HPV types.
In contrast to HPV16, HPV18 has been reported to be
integrated into the cell genome even in pre-neoplastic
lesions, becoming more invasive, and possibly more
aggressive (Badaracco et al., 2002). TNF-a represents a
key regulatory cytokine involved in the regression of benign
tumors and playing a pivotal role in the control of dysplastic
cervical lesions infected with high-risk HPV types (Bach-
mann et al., 2002). In addition, TNF-a possesses growth-
inhibitory functions in non-malignant HPV-infected kerati-
nocytes, suppressing E6 and E7 viral oncogene transcription
and inducing the expression of monocyte chemoattractant
protein-1 (MCP-1) (Rfsl et al., 1994). Cervical carcinoma
cells are completely refractory to triggering MCP-1 gene
expression, despite functional TNF-a signaling (Finzer et
al., 2000). Furthermore, conversion to carcinogenicity is
accompanied by resistance against TNF-a, a cytokine
capable of selectively suppressing HPV18 transcription in
formerly non-malignant cells (Soto et al., 1999). These
literature findings together with the results of the present
study suggest that HPV 18 may be more difficult to be
cleared in relation to HPV-16.
In conclusion, the concomitance of HPV16 and HIV
infection was associated with increased intralesional IL-10
levels. Similarly, the presence of HPV18, irrespective of HIV
status, was associated with decreased TNF-a and IFN-g
intralesional levels. Taken together, these findings may
contribute to SIL installation. Considering that this study
was originally designed as a transversal study, further studies
including larger number of patients should be performed to
address the specific issue of how much the specific HPV
types might influence the cytokine intralesional levels.Materials and methods
Study population
Patients
Forty-two women aged 16–46 years (median = 27)
presenting with distinct SIL grades were selected from
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Hospital of the Faculty of Medicine of Ribeira˜o Preto,
University of Sa˜o Paulo, Brazil, from October 2001 to
November 2002. Twenty-two patients exhibited LSIL
(10 HIV positive and 12 HIV negative) and 20 HSIL
(10 HIV positive and 10 HIV negative). Of the LSIL
group, 12/20 (60%) of patients reported to be current
smokers and 2/20 (10%) were using oral contraceptive.
Of the HSIL group, 10/13 (77%) patients reported to
be current smokers and 1/13 (8%) was using oral
contraceptives.
Twenty patients aged 16–40 years (median = 28) were
infected with HIV and 22 aged 16–40 (median = 26.5) were
not. According to the Centers for Disease Control and
Prevention (CDC) classification (Centers for Diseases
Control, 1992), 8 of the 20 HIV-positive patients (40%)
were asymptomatic and 12/20 (60%) presented AIDS and
were receiving highly active antiretroviral therapy
(HAART) at the time of the study. Regarding the CD4
T-cell count, 5/20 (25%) exhibited counts higher than 500/
AL, 13/20 (65%) between 500 and 200/AL, and 2/20 (10%)
lower than 200/AL.
Ethical aspects
The Medical Ethics Committee of the University
Hospital of Faculty of Medicine of Ribeira˜o Preto,
Brazil, approved the study protocol (process number
6597/2001), and informed consent was obtained from all
individuals.
Sample collection
Colposcopically directed cervical biopsies were col-
lected and cervical specimens were cut in two sections,
one fixed with formalin and stained with hematoxylin-
eosin (Sigma, St. Louis, MO, USA) to analyze tissue
morphology and integrity. Two pathologists blinded to
one another reviewed all the histopathological diagno-
ses. Cervical biopsies from HIV-negative or HIV-
positive women were stratified into 2 groups: LSIL
(cervical intraepithelial neoplasia I and HPV DNA
positive) and HSIL (cervical intraepithelial neoplasia
II–III and in situ carcinoma). The other cervical
fragment was immediately immersed in liquid nitrogen
and maintained at 70 8C until use. Cervical DNA was
used for HPV detection and typing, and cervical protein
was used for the quantification of intralesional cytokine
levels.
DNA and protein extraction
Intralesional protein and genomic DNA from cervical
biopsies were extracted simultaneously using Trizol
(GIBCO, RD, USA) according to manufacturer instruc-
tions and maintained at 70 8C until quantification.Intralesional cytokine levels
A double-sandwich ELISA was performed to measure
the concentration of TNF-a, INF-g, and IL-10 in protein
obtained from cervical biopsies, as previously described
(Cunha et al., 2003), with minor modifications. Briefly,
microtiter plates (Nunc-Maxisorb) were coated overnight at
4 8C with 50 AL (2 Ag/mL) of antihuman antibody specific
for these cytokines and washed three times with PBS
containing 0.1% Tween 20 (Sigma). Wells containing
blocking buffer (PBS plus 0.1% Tween 20 and 1.0% filtered
BSA) were incubated for 2 h at 4 8C and then washed three
times with PBS plus 0.1% Tween 20. Samples in a volume
of 50 AL were added to each well. The plates were
incubated overnight at 4 8C and then washed three times
with PBS plus 0.1% Tween 20. Then, 50 AL (1 Ag/mL) of a
polyclonal anti-cytokine antibody conjugated with biotin
diluted in blocking buffer was added to each well. The
plates were then incubated for 1 h at 37 8C. After three
washes with PBS and 0.1% Tween 20, the reaction products
were detected with an avidin-biotin-peroxidase complex
(vector). The color of the reaction was developed using o-
phenylenediamine dihydrochloride (Sigma) and read at 490
nm. The concentrations of cytokines in the samples were
calculated from a standard curve of human recombinant
cytokine. Although fragment size was closely similar, we
adjusted the cytokine concentration according to the DNA
concentration obtained from the same fragment and the
results were expressed as pg/50 AL.
HPV DNA detection and typing
DNA was amplified using 12.5 pM of each dNTP, 25
pM of each primer, 1.5 U Taq DNA polymerase (BioTools,
Madrid, Spain), 5 AL of 10 enzyme buffer, 20 Ag of
genomic DNA, and distilled deionized water to complete a
total volume of 25 AL. The mixture was processed in a
thermocycler apparatus (MJ Research, MA, USA) under
the following cycling conditions: 1 cycle at 95 8C for 5
min, then 30 cycles at 95 8C for 30 s, 55 8C for 30 s and
72 8C for 1 min, and finally 1 cycle at 72 8C for 10 min,
and then, at 4 8C indefinitely.
Several pairs of primers were used. The primers GP5 and
GP6 (Nijders et al., 1990), which amplify small DNA
fragments, and the primers MY09 and MY11 (Manos,
1989), which amplify longer DNA fragments, were used for
generic HPV amplification.
Since HPV 16 and HPV 18 are the types most
frequently associated with SIL, attention was focused on
them. The primers HPV16E7.667/HPV16E7.774 specific
for HPV16 and HPV18E7.696/HPV18E7.799 (Wal-
boomers et al., 1999) specific for HPV18 were also used,
considered as positive only unambiguous amplifications.
Lack of amplification with these primers or ambiguous
amplifications after several repetitions was assigned as other
HPV types.
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electrophoresed at 200 mA for 2 h, and stained with AgNO3
by the method of Sanguinetti et al. (1994).
Statistical analysis
According to the distribution of the data concerning the
intralesional cytokine levels, the unpaired t test or the
Mann–Whitney test (MW) was used. The Instat program
(GraphPad software, CA, USA) was used for all these
analyses. In a 95% confidence interval, P values less than or
equal to 0.05 were considered to be significant.Acknowledgments
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